α-Tocopheryl Succinate Inhibits Osteolytic Bone Metastasis of Breast Cancer by Suppressing Migration of Cancer Cells and Receptor Activator of Nuclear Factor-κB Ligand Expression of Osteoblasts

Abstract

BackgroundBreast cancer is one of the most common cancers affecting women and has a high incidence of bone metastasis, causing osteolytic lesions. The elevated expression of receptor activator of nuclear factor-κB ligand (RANKL) in cancer activates osteoclasts, leading to bone destruction. We previously reported that α-tocopheryl succinate (αTP-suc) inhibited interleukin-1-induced RANKL expression in osteoblasts. Here, we examined the effect of αTP-suc on osteolytic bone metastasis in breast cancer.MethodsTo examine the effect of αTP-suc on the metastatic capacity of breast cancer, MDA-MB-231-FL cells were injected into the left cardiac ventricle of BALB/c nude mice along with intraperitoneal injection of αTP-suc. The mice were then analyzed by bioluminescence imaging. To investigate the effect of αTP-suc on osteolysis, 4T1 cells were directly injected into the femur of BALB/c mice along with intraperitoneal injection of αTP-suc. Microcomputed tomography analysis and histomorphometric analysis of the femora were performed.ResultsαTP-suc inhibited cell migration and cell growth of 4T1 cells. In line with these results, bone metastasis of MDA-MB-231-FL cells was reduced in mice injected with αTP-suc. In addition, αTP-suc decreased osteoclastogenesis by inhibiting 4T1-induced RANKL expression in osteoblasts. Consistent with these results, 4T1-induced bone destruction was ameliorated by αTP-suc, with in vivo analysis showing reduced tumor burden and osteoclast numbers.ConclusionsOur findings suggest that αTP-suc may be efficiently utilized to prevent and treat osteolytic bone metastasis of breast cancer with dual effects.

Enhanced Prevention of Breast Tumor Metastasis by Nanoparticle‐Delivered Vitamin E in Combination with Interferon‐Gamma

“…The 4T1 cell migration ability was examined in a 700–1000 µm wound model, as shown in Figure 3E,F and Figure S4 (Supporting Information). In general, free α‐TOS or NP‐TOS15‐treated cells migrated at a much shorter distance (50–100 µm) in 24 h, suggesting that α‐TOS significantly inhibited cancer cell migration 33. Meanwhile, exposure to IFN‐γ (5 ng mL −1 ) decreased the migration distance from 184 to 75 µm (Figure 3E,F), similarly in previous studies 34.…”

Extracts ofFlavoparmeliasp. Inhibit Receptor Activator of Nuclear Factor-κB Ligand-Mediated Osteoclast Differentiation

“…In addition, EFV reduced the levels of TRAP, DC-STAMP, and cathepsin K expression, which are osteoclast formation and activation-related molecules, by decreasing NFATc1. [3738394041] And we confirmed that RANKL-induced bone resorption was decreased by EFV in vitro. This means that EFV inhibits and reduces the formation and activity of osteoclasts.…”

Causal Inference Network of Genes Related with Bone Metastasis of Breast Cancer and Osteoblasts Using Causal Bayesian Networks

“…NFKB2, one of the plausible upstream genes, encode NF-κB protein that is a transcription factor known as a regulator of the immune system and promotes epithelial-to-mesenchymal transition and the metastasis of BC. [304445] Although the protein encoded by UBIAD1 gene was reported as bladder tumor suppressor protein, there was no report about its role in tumor development or the progression of HEBP1. [46] The UBIAD1 gene had 3 direct cause (parent) genes in S ◆ , i.e., DVL1, INPP1, and MAPK3.…”